Gadolinium

InnoCare Releases 2023 Results and Business Highlights

Retrieved on: 
Thursday, March 28, 2024
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, QD, Tafasitamab, Patient, B-cell lymphoma, NDA, SLE, POC, IND, Clinical trial, Bone marrow, IKZF1, Phase, Therapy, IGA, MCD, Dexamethasone, MCL, Neuromyelitis optica spectrum disorder, IKZF3, AML, NMOSD, Outline of health sciences, DLT, Cancer, Autoimmune disease, Safety, TYK2, HSA, NRDL, BLA, Follicular lymphoma, Food, GC, Development, Multiple sclerosis, PD, CRBN, Public, Gordon Ramsay's Bank Balance, Multiple myeloma, ITP, BCL2, Leukemia, Cmax, Gadolinium, HKEX, SRI, AAD, Proteinuria, DLBCL, Glucocorticoid, IVIG, Loss, European Hematology Association, American Academy, EHA, Lenalidomide, NHL, Non-Hodgkin lymphoma, CCR8, US FDA, BTK, NRS, Pharmaceutical industry

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.

Key Points: 
  • InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
  • In 2023, InnoCare has continued to advance its robust pipeline across various clinical stages, continuously unleashing the power of innovation to meet unmet medical needs.
  • In June 2023, the ITP Phase II result was orally presented at the European Hematology Association (EHA) 2023 Hybrid Congress.
  • InnoCare was approved by the Hong Kong Stock Exchange to remove "B" from the stock code from May 12, 2023.

United States Cancer Contrast Media (Gadolinium, Iodinated) Market Size, Share & Trends Analysis Report 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2024
Health, Oncology, Diagnosis, Breast cancer, Gadolinium, Medicine, MRI, Growth, Prevalence, Agent handling, Patient, Public, Private sector, GE HealthCare, Google Images, Lung cancer, Investment, Smoking, Contrast (vision), Air pollution, USD, Government, Iodine, Medical imaging

The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S. Cancer Contrast Media Market Size, Share & Trends Analysis Report by Type (Gadolinium-based Contrast Media, Iodinated Contrast Media), Modality (Nuclear Imaging, CT scans), Application (Breast Cancer, Lung Cancer), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
  • The U.S. cancer contrast media market is anticipated to reach USD 1.53 billion by 2030 and is anticipated to expand at a CAGR of 11.7% from 2024 to 2030.
  • Thus, these factors collectively propel the growth of U.S. cancer contrast media market.
  • Iodinated contrast media dominated the type segment with a share of 39.5% in 2023 owing to the increasing medical imaging procedures.

Globex Exploration Update on Virgin Mountain Rare Earth & Beryllium Project, Arizona, USA

Retrieved on: 
Tuesday, February 13, 2024
Thulium, Virginity, Yttrium, GMX, Beryllium, Radioactive decay, Geo, Erbium, Niobium, Density, AAL, Terbium(III) oxide, Gadolinium, Toronto Stock Exchange, ASARCO, Ytterbium, LREE, Silver, Tantalum, Assay, Dysprosium, Wolverine, Terbium, Holmium, Virgin Mountain, Asarco, Chrysoberyl, Uranium, Beryl, Geology, Element, REE, Virgin Mountains, Lutetium, Anomaly, ICP-OES, Rare-earth element

The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.

Key Points: 
  • The Virgin Mountain rare earth & beryllium property is located in the Arizona portion of the Virgin Mountain range, about 120 km northeast of Las Vegas, Nevada.
  • Past exploration activities for uranium and later for rare earth elements (REE) initiated in the 1940’s and ended in 1991.
  • In the 1950’s and 1960’s the Virgin Mountains Be-bearing pegmatites had been explored intensely for beryllium, but never came into production.
  • Rare Earth (REE) ± U & Th mineralization is hosted in migmate-gneiss and interlayered thin schist layers, locally also in pegmatite dikes.

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, MRI, INN, Risk, Interferon beta-1a, Immune system, Fatigue, Infection, Registry, ATC, Antibody, Gadolinium, Disability, Multiple sclerosis, International, Attack, Spinal cord, Disease, Common, PML, Nose, Headache, Nausea, Brain, Language, Urinary tract infection, Inflammation, Cancer, Nerve, Dizziness, Skin cancer, Allergy, DMT, Death, European Medicines Agency, Nervous system, Select, Carcinoma, Safety, Encephalitis, Anatomy, Arthralgia, Sclerosis, IIA, Magnetic resonance imaging, Medical device

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
CNS, Lung, Health, Neck, Prostate, Medical University of Vienna, Breast, Brain, Safety, Food, European Medicines Agency, Paediatric-use marketing authorisation, European Commission, Head, University, Medical imaging, Human, Liver, Spine, GBCA, Google Images, PICTURE, Gadolinium, EMA, Civil service commission, Patient, Marketing authorisation, European, Gadobutrol, Neurology, FDA, Kidney, Pancreas, European Committee for Standardization, CHMP, BBB, Monroe Dunaway Anderson, Committee, Pathology, Gastroenterology, MRI, Central nervous system, MD Anderson Cancer Center, Medical school, Environment, Vaccine, Rare-earth element

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.

Key Points: 
  • Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.
  • MILAN, Dec. 11, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announces that on December 7, 2023 the European Commission (EC) has granted the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union (EU).
  • 1,2
    "The final approval of gadopiclenol by the European Commission marks a significant milestone in the field of diagnostic imaging.
  • This innovation benefits healthcare providers but also, more importantly, patients who undergo MRI scans and those living with chronic conditions.

The European Commission granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
CNS, Lung, Health, Neck, Prostate, Medical University of Vienna, Breast, Brain, Safety, Food, European Medicines Agency, Paediatric-use marketing authorisation, European Commission, Head, University, Medical imaging, Human, Liver, Spine, GBCA, Google Images, PICTURE, Gadolinium, EMA, Civil service commission, Patient, Marketing authorisation, European, Gadobutrol, Neurology, FDA, Kidney, Pancreas, European Committee for Standardization, CHMP, BBB, Monroe Dunaway Anderson, Committee, Pathology, Gastroenterology, MRI, Central nervous system, MD Anderson Cancer Center, Medical school, Environment, Vaccine, Rare-earth element

Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.

Key Points: 
  • Following the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and the recommendation sent by EMA to the European Committee (EC), the EC has granted Marketing Authorisation for Vueway® (gadopiclenol) in the European Union.
  • MILAN, Dec. 11, 2023 /PRNewswire/ -- Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announces that on December 7, 2023 the European Commission (EC) has granted the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union (EU).
  • 1,2
    "The final approval of gadopiclenol by the European Commission marks a significant milestone in the field of diagnostic imaging.
  • This innovation benefits healthcare providers but also, more importantly, patients who undergo MRI scans and those living with chronic conditions.

Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European Union

Retrieved on: 
Monday, December 11, 2023
Syringe, Safety, Regulatory affairs, European Medicines Agency, Aulnay-sous-Bois, European Commission, Ageing, GBCA, Gadolinium, Civil service commission, Medicine, European, FDA, CHMP, BBB, Marketing, Committee, Pathology, Marans, Charente-Maritime, Person, Medical imaging, Seine-Saint-Denis, MRI, Radiology

The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.

Key Points: 
  • The marketing authorisation (MA) for Elucirem™ (Gadopiclenol) was granted to Guerbet by the European Commission based on the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dated 12 October 2023.
  • It will be marketed by Guerbet in the European Union in the following forms: vials and prefilled syringes.
  • "After its approval by the FDA for the American market, the European marketing authorisation for Elucirem™ reinforces our strategic perspective: combining medical innovation and environmental commitment.
  • This authorisation is ground-breaking for Medical Imaging in Europe," concludes David Hale, Guerbet CEO.

Fastmarkets launches rare earths prices for the energy transition

Retrieved on: 
Thursday, November 2, 2023
Mining, EV, Praseodymium, ESG, Neodymium magnet, Neodymium, Wind, PRA, Environment, Dysprosium, ICE, Terbium, EVS, Gadolinium, Renewable energy, Rare-earth element

Global reserves of the four rare earth elements needed for high-performance NdFeB magnets for EV motors -- neodymium, praseodymium, dysprosium and terbium -- are plentiful enough to support the energy transition for the foreseeable future. But complex and opaque supply chains, unexplained price volatility, regional concentration and geopolitical tensions are making it harder for business planners and procurement managers to make timely decisions in a rapidly evolving economic, regulatory and ESG environment.

Key Points: 
  • Global reserves of the four rare earth elements needed for high-performance NdFeB magnets for EV motors -- neodymium, praseodymium, dysprosium and terbium -- are plentiful enough to support the energy transition for the foreseeable future.
  • Building upon its track record of world-beating coverage and prices for battery raw materials markets, Fastmarkets has launched five weekly rare earth prices.
  • "Introducing these new rare earth prices is a landmark moment for Fastmarkets and a reflection of our unwavering commitment to bringing transparency and reliability to commodity markets," Fastmarkets CEO Raju Daswani said.
  • *Heavy rare earths are added to NdFeB magnets to maintain performance and efficiency at higher temperatures in motor applications.

CENTRAL AMERICA NICKEL ANNOUNCES FILING OF RARE EARTH EXTRACTION PATENT USING PROPRIETARY ULTRASOUND TECHNOLOGY

Retrieved on: 
Monday, October 30, 2023
Rare earth, Praseodymium, Patent, Uranium, Radioactive decay, Neodymium, Extraction, DRC, South Africa, PCT, Democratic republic, Lighting, CO2, Electronics, Gadolinium, Congo, Iridium, Thorium, Rare-earth element, Battle of Anchem

MONTREAL, Oct. 30, 2023 /PRNewswire/ -- Central America Nickel Inc. (the "Company" or "CAN") is pleased to announce that it has filed a PCT application (PCT/CA2023/051387) and a patent application in the Democratic Republic of the Congo titled "Process for Extraction of Rare Earth Elements" for the extraction of rare earth elements using the Company's Ultrasound Assisted Extraction (UAEx) technology.

Key Points: 
  • MONTREAL, Oct. 30, 2023 /PRNewswire/ -- Central America Nickel Inc. (the "Company" or "CAN") is pleased to announce that it has filed a PCT application (PCT/CA2023/051387) and a patent application in the Democratic Republic of the Congo titled "Process for Extraction of Rare Earth Elements" for the extraction of rare earth elements using the Company's Ultrasound Assisted Extraction (UAEx) technology.
  • The patent-filed process is a combination of a process for the extraction and recovery of rare earth elements, and the selective extraction and separation of radioactive components (uranium and thorium) from rare earth components with the use of CAN's ultrasound technology, the Ultrasound Assisted Extraction (UAEx), as a process intensification method.
  • Given the complexity of extracting and refining rare earths elements, the use of CAN's proprietary technology and processes could represent a major extractive industry advancement.
  • Rare earths are listed on the critical mineral lists outlined by the governments of Canada and the United States.

Guerbet: CHMP positive opinion

Retrieved on: 
Thursday, October 12, 2023
III, European, European Commission, Committee for Medicinal Products for Human Use, CHMP, Radiology, Agent handling, Brain, Breast, Pancreas, Medicine, Central nervous system, Liver, Magnetic resonance imaging, European Medicines Agency, Spine, EMA, FDA, Kidney, Committee, Lung, Human, MRI, Tissue, Civil service commission, CNS, Prostate, Gadolinium, Patient, Regulatory affairs, Medical imaging, Health, EU

Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.

Key Points: 
  • Approved by the FDA in September 2022, Elucirem™ is produced in France and in the USA.
  • Villepinte, France, 12 october 2023: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion concerning the granting of a marketing authorisation for Elucirem™ (Gadopiclenol) in the European Union (EU) for use in adults and children aged 2 years and over for MRI with contrast enhancement.
  • The positive opinion from the CHMP is essentially based on data from two phase III clinical trials completed in March 2021.
  • "This positive opinion from the CHMP,
    at the end of 2023, will bring European patients and health professionals